Role of telomeres and telomerase in aging and cancer

Cancer Discovery

Volumn 6, Issue 6, 2016, Pages 584-593

  Shay, Jerry W ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE; TELOMERASE INHIBITOR; TELOMERASE REVERSE TRANSCRIPTASE;

AGING; CANCER GROWTH; CANCER SUSCEPTIBILITY; CELL PROLIFERATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HUMAN; HUMAN EMBRYONIC STEM CELL; MALIGNANT TRANSFORMATION; NEOPLASM; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT; REVIEW; SENESCENCE; SOMATIC MUTATION; SPONTANEOUS MUTATION; TELOMERE; TELOMERE LENGTH; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; TUMOR GROWTH; WHOLE GENOME SEQUENCING; ANIMAL; APOPTOSIS; CELL TRANSFORMATION; GENETICS; METABOLISM; TELOMERE HOMEOSTASIS; TELOMERE SHORTENING;

AGING; ANIMALS; APOPTOSIS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; NEOPLASMS; TELOMERASE; TELOMERE; TELOMERE HOMEOSTASIS; TELOMERE SHORTENING;

EID: 85011971596     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-16-0062     Document Type: Review

References (104)

1. Greider CW., Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985;43:405-13.
2. Kim NW., Piatyszek MA., Prowse KR., Harley CB., West MD., Ho PL., et al. Specific association ofhuman telomerase activity with immortal cells and cancer. Science 1994;266:2011-15.
3. Shay JW., Bacchetti S. A survey of telomerase in human cancer. Eur J Cancer 1997;33:787-91.
4. Lingner J., Hughes TR., Shevchenko A., Mann M., Lundblad V., Cech TR. Reverse transcriptase motifs in the catalytic subunit of telomer-ase. Science 1997;276:561-7.
5. Nakamura TM., Morin GB., Chapman KB., Weinrich SL., Andrews WH., Lingner J., et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997; 277: 955-9.
6. Meyerson M., Counter CM., Eastonn EN., Ellisen LW., Steiner P. hEST2. the putative human telomerase catalytic subunit gene., is upregulated in tumor cells and during immortalization. Cell 1997; 90: 785-95.
7. Harley CB., Futcher BA., Greider CW. Telomeres shorten during aging of human fibroblasts. Nature 1990;345:458-60.
8. Hastie ND., Dempster M., Dunlop MG., Thompson AM., Green DK., Allshire RC. Telomere reduction in human colorectal carcinoma and with ageing. Nature 1990; 346: 866-8.
9. Lindsey J., McGill NI., Lindsey LA., Green DK., Cooke HJ. In vivo loss of telomeric repeats with age in humans. Mut Res 1991;256:45-8.
10. de Lange T., Shiue L., Myers RM., Cox DR., Naylor SL., Killery AM., et al. Structure and variability of human chromosome ends. Mol Cell Biol 1990;10:518-27.
11. Shay JW., Wright WE. The reactivation of telomerase activity in cancer progression. Trends Genet 1996;12:129-31.
12. Kim N-W., Harley CB., Prowse KR., Weinrich SL., Piatyszek MA., Wright WE., et al. Telomeres., telomerase and cancer. Science 1995; 268: 1115-7.
13. Wright WE., Pereira-Smith OM., Shay JW. Reversible cellular senescence: A two-stage model for the immortalization of normal human diploid fibroblasts. Mol Cell Biol 1989;9:3088-92.
14. Counter CM. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 1992; 11: 1921-9.
15. Blackburn E. Telomerases. Annual Rev Biochem 1992; 61: 113-29.
16. Jiang J., Chan H., Cash DD., Miracco EJ., Ogorzalek RR., Loo HE., et al. Structure of Tetrahymena telomerase reveals previously unknown subunits., functions and interactions. Science 2015; 350: 529-34.
17. Wu RA., Dagdas YS., Yilmaz ST., Yildiz A., Collins K. Single-molecule imaging of telomerase reverse transcriptase in human telomerase holoenzyme and minimal RNP complexes. eLife 2015;4:e08363.
18. Muller HJ. The remaking of chromosomes. In: Studies of genetics: The selected papers of HJ Muller., Indiana University Press., Bloomington 1962; 384-408.
19. McClintock B. The stability of broken ends of chromosomes in Zea mays. Genetics 1941;26:234-82.
20. Blackburn EH., Gall JG. A tandemly repeated sequence at the termini of the extrachromosomal ribosomal RNA genes in Tetrahymena. J Mol Biol 1978; 120: 33-53.
21. Moyzis RK., Buckingham JM., Cram LS., Dani M., Deaven LL., Jones MD., et al. A highly conserved repetitive DNA sequence (TTAGGG)n., present at the telomeres of human chromosomes. Proc Natl Acad SciUS A 1988;85:6622-6.
22. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 2005; 19: 2100-10.
23. Palm W., de Lange T. How shelterin protects mammalian telomeres. Ann Rev Genet 2008;42:301-34.
24. Griffith JD., Comeau L., Rosenfield S., Standel RM., Bianchi A., Moss H., et al. Mammalian telomeres end in a large duplex loop. Cell 1999; 97: 503-14.
25. Watson JD. Origin of concatemeric T7 DNA. Nature., New Biol 1972;239:197-201.
26. Olovnikov AM. A theory of margintomy: The incomplete copying of template margin in enzymes synthesis of polynucleotides and biological significance of the problem. J Theoret Biol 1973; 41: 181-90.
27. Zou Y., Sfeir A., Gryaznov SM., Shay JW., Wright WE. Does a sentinel or groups of short telomere determine replicative senescence? Mol Biol Cell 2004; 15: 3709-18.
28. Fumagalli M., Rossiello F., Clerici M., Barozzi S., Cittaro D., Kaplunov JM., et al. DNA damage is irreparable and causes persistent DNA-damage-response activation. Nat Cell Bio 2012; 14: 355-65.
29. Von Zglinicki T., Saretzki G., Ladhoff J., d’Adda di Fagagna F, Jackson SP. Human cell senescence as a DNA damage responses. Mechan Ageing Devel 2005; 26: 111-7.
30. Tchkonia T., Zhu Y., van Deursen J., Campisi J., Kirkland JL. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest 2013; 123: 966-72.
31. Shay JW., Wright WE. Historical claims and current interpretations of replicative aging. Nat Biotech 2002; 20: 682-8.
32. Wright WE., Shay JW. The two-stage mechanism controlling cellular senescence and immortalization. Exp Gerontol 1992; 27; 383-9.
33. Shay JW., Wright WE., Werbin H. Defining the molecular mechanism of human cell immortalization. Biochim Biophys Acta. 1991; 1072: 1-7.
34. Harley CB. Telomere loss: mitotic clock or genetic time bomb? Mut Res 1991; 256: 271-82.
35. Sandin S., Rhodes D. Telomerase Structure. Curr Opin Struct Biol 2014; 25: 104-10.
36. Blackburn EH., Epel ES., Lin J. Human telomere biology: A contributory and interactive factor in aging., disease risks., and protection. Science. 2015: 350; 1193-8.
37. Bojesen SE., Pooley KA., Johnatty SE., Beesley J., Michailidou K., Tyrer JP., et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet 2013; 45; 371-384.
38. Heidenreich B., Rachakonda PS., Hemminki K., Kumar R. TERT promoter mutations in cancer development. Current Opin Genet Develop 2014;24:30-7.
39. Huang FW., Hodis E., Xu MJ., Kryukov GV., Chin L., Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science 2013;339:957-9.
40. Chiba K., Johnson JZ., Vogan JM., Wagner T., Boyle JM., Hockemeyer D. Cancer-associated TERT promoter mutations abrogate telomerase silencing. eLife 2015;4 e07918.
41. Killela PJ., Reitman ZJ., Jiao Y., Bettegowda C., Agrawal N., Diaz LA Jr., et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 2013;110:6021-6.
42. Vinagre J., Almeida A., Populo H., Batista R., Lyra J., Pinto V., et al. Frequency of TERT promoter mutations in human cancers. Nature Comm 2013; 4: 2185.
43. Horn S., Figl A., Rachakonda PS., Fischer C., Sucker A., Gast A., et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013; 339: 959-61.
44. Stern JL., Theodorescu D., Vogelstein B., Papadopoulos N., Cech TR Mutation of the TERT promoter switch to active chromatin., and monoallelic TERT expression in multiple cancers. Genes Dev 2015; 29: 1-6.
45. Hiyama E., Hiyama K., Yokoyama T., Matsuura Y., Piatyszek MA., Shay JW. Correlating telomerase activity levels with human neuroblastoma outcomes. Nature Med 1995;1:249-57.
46. Tabori U., Vukovic B., Zielenska M., Hawkins C., Braude I., Rutka J., et al. The role of telomere maintenance in the spontaneous growth arrest of pediatric low-grade gliomas. Neoplasia 2006; 8: 136-42.
47. Hiyama E., Hiyman K., Ohtsu K., Yamaoka H., Ichikawa T., Shay JW., et al. Telomerase activity in neuroblastoma: Is it a prognostic indicator of clinical behavior? Eur J Cancer 1997; 33: 1932-36.
48. Shay JW., Reddel RR., Wright WE. Cancer and telomerase: An ALTernative to telomerase. Science 2012; 336: 1388-1390.
49. Ouellette MM., Liao M., Herbert B-S., Johnson M., Holt SE., Liss HS., et al. Senescent telomere lengths in fibroblasts immortalized by limiting amounts of telomerase. J Biol Chem 2000;275:10072-6.
50. Steinert S., Shay JW., Wright WE. Transient expression of human tel-omerase extends the lifespan of normal human fibroblasts. Biochem Biophys Res Commun 2000; 273: 1095-8.
51. Peifer M., Hertwig F., Roel F., Dreidax D., Gartlgruber M., Menon R., et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature 2015;526:700-4.
52. Wong MS., Wright WE., Shay JW. Alternative splicing regulation of telomerase: a new paradigm? Trends Genet 2015; 30; 10: 430-8.
53. Shay JW., Wright WE. When do telomeres matter? Science 2001;291: 839-40.
54. Wright WE., Shay JW. Cellular senescence as a tumor-protection mechanism: the essential role of counting. Curr Opin Genet Develop 2001; 11: 98-103.
55. Shay JW., Wright WE. Quantitation of the frequency of immortalization of normal diploid fibroblasts by SV40 large T-antigen. Exp Cell Res 1989;184:109-18.
56. Cesare AJ., Reddel RR. Alternative lengthening of telomeres: models., mechanisms and implications. Nat Rev Genet 2010;11:319-30.
57. Ramirez R., Morales CP., Herbert B-S., Rhode JM., Passon C., Shay JW., et al. Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions. Gen Develop 2001;15: 398-403.
58. Wong MS., Chen L., Foster C., Kainthla R., Shay JW., Wright WE. Regulation of hTERT (telomerase) alternative splicing: a new target for chemotherapy. Cell Rep 2013; 3: 1028-35.
59. Wong MS., Shay JW., Wright WE. Regulation of human telomerase splicing by RNA:RNA pairing. Nature Commun 2014;5:3306.
60. Cao Y., Bryan TM., Reddel RR Increased copy number of the TERT and TERC telomerase subunit genes in cancer cells. Cancer Sci 2008;99:1092-9.
61. Shay JW., Wright WE. Implications of mapping the human telomerase genes (hTERT) as the most distal gene on chromosome 5p. Neoplasia 2000; 2: 195-6.
62. Wright WE., Piatyszek MA., Rainey WE., Byrd W., Shay JW. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet 1996;18:173-9.
63. Robin JD., Ludlow AT., Chen M., Magdinier F., Batten K., Holohan B. et al. Telomere looping: a new paradigm for the regulation of gene expression with progressive telomere shortening. Genes Dev 2014; 28: 2464-76.
64. Robin JD., Ludlow AT., Batten K., Gaillard M-C., Stadler G., Magdinier F., et al. SORBS2 transcription is activated by telomere position effect-over long distance upon telomere shortening in muscle cells from patients with fasciscapulohumeral dystrophy. Genome Res 2015; 25: 1781-90.
65. Bodnar AG., Ouellette M., Frolkis M., Holt SE., Chiu CP., Morin GB., et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279: 349-52.
66. Morales CP., Holt SE., Ouellette M., Kaur KJ., Wilson KS., White MA., et al. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nat Genet 1999; 21: 115-8.
67. Julin B., Shui I., Heaphy CM., Joshu CE., Meeker AK., Giovannucci E., et al. Circulating leukocyte telomere length and risk of overall and aggressive prostate cancer. Br J Cancer 2015;112:769-76.
68. Nan H., Du M., De Vivo I., Manson JE., Liu S., McTiernan A., et al. Shorter telomeres associate with a reduced risk of melanoma development. Cancer Res 2011;71:6758-63.
69. Lynch SM., Major JM., Cawthon R., Weinstein SJ., Virtamo J., Lan Q., et al. A prospective analysis of telomere length and pancreatic cancer in the alpha-tocopherol beta-carotene cancer (ATBC) prevention study. IntJ Cancer 2013;133:2672-80.
70. Qu S., Wen W., Shu XO., Chow WH., Xiang YB., Wu J., et al. Association of leukocyte telomere length with breast cancer risk: nested case-control findings from the Shanghai Women’s Health Study. Am J Epidemiol 2013;177:617-24.
71. Seow WJ., Cawthon RM., Purdue MP., Hu W., Gao YT., Huang WY., et al. Telomere length in white blood cell DNA and lung cancer: a pooled analysis of three prospective cohorts. Cancer Res 2014; 74: 4090-8.
72. Peto R. Quantitative implications of the approximate irrelevance of mammalian body size and lifespan to lifelong cancer risk. Philos Trans RSoc Lond B Biol Sci 2015;370:2015.0198.
73. Schiffman J., Maley CC., Nunney L., Hochberg M., Breen M., eds. Cancer across life: Peto’s paradox and the promise of comparative oncology. Philos Trans R Soc Lond B Biol Sci. (theme issue) 2015; 370:1673.
74. Caulin AF., Maley CC. Peto’s paradox: evolution’s prescription for cancer prevention. Trends Ecol Evol 2011;26:175-82.
75. Gomes NMV., Ryder OA., Houck ML., Charter SJ., Walker W., Forsyth NR., et al. The comparative biology of mammalian telomeres: ancestral states and functional transitions. Aging Cell 2011;10:761-8.
76. Seluanov A., Chen Z., Hine C., Sasahara TH., Ribeiro AA., Catania KC., et al. Telomerase activity coevolves with body mass not lifespan. Aging Cell 2007; 6: 45-52.
77. Gorbunova V., Seluanov A., Zhang Z., Gladyshev VN., Vijg J. Comparative genetics of longevity and cancer: insights from long-lived rodents. Nat Rev Genet 2014; 15: 531-40.
78. Abegglen LM., Caulin AF., Chan A., Lee K., Robinson R., Campbell MS., et al. Potential mechanisms for cancer resistance in elephants and comparative cellular response to DNA damage in humans. JAMA 2015;314:1850-1860.
79. Keane M., Semeiks J., Webb AE., Li YI., Quesada V., Craig T., et al. Insights into the evolution of longevity from the bowhead whale genome. Cell Rep 2015;10:112-22.
80. Wylie A., Jones AE., D'Brot A., Lu W-J., Kurtz P., Moran JV., et al. p53 genes function to restrain mobile elements. Genes Dev 2015;30: 1-14.
81. Sahin E., DePinho RA. Linking functional decline of telomeres., mitochondria and stem cells during ageing. Nature 2010;464:520-8.
82. Greaves M. Evolutionary determinants of cancer. Cancer Discov 2015;5:806-20.
83. Greaves M., Ermini L. Evolutionary adaptation to risk of cancer: evidence from cancer resistance in elephants. JAMA 2015;314:1806-7.
84. Ludlow AT., Robin JD., Sayed M., Litterst CM., Shelton DN., Shay JW., et al. Quantitative telomerase enzyme activity determination using droplet digital PCR with single cell resolution. Nucleic Acids Res., 2014; 42: e104.
85. Meeker AK., Gage WR., Hicks JL., Simon I., Coffman JR., Platz EA., et al. Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridization and immu-nostaining. Am J Pathol 2002;160:1259-68.
86. Canela A., Vera E., Klatt P., Blasco MA. High-throughput telomere length quantification by FISH and its application to human populations studies. Proc Natl Acd Sci USA 2006;104:5300-5.
87. Rufer N., Dragowska W., Thornbury G., Roosnek E., Lansdorp PM. Telomere length dynamics in human lymphocytes subpopulations measured by flow cytometry. Nature Biotech 1998; 16: 743-7.
88. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res 2002; 30: e47.
89. Baird DM., Rowson J., Wynford-Thomas D., Kipling D. Extensive allelic variation and ultrashort telomeres in senescent human cells. Nature Genet 2003; 33: 203-7.
90. Bendix L., Horn PB., Jensen UB., Rubelj I., Kolvraa S. The load of short telomeres., estimated by a new method., Universal STELA., correlates with number of senescent cells. Aging Cell 2010;9:383-97.
91. Holohan B., Hagiopian MM., Lai TP., Huang E., Friedman DR., Wright WE., et al. Perifosine as a potential novel anti-telomerase therapy. Oncotarget 2015.
92. Ding Z., Mangino M., Aviv A., Spector T., Durbin R., UK10K Consortium. Estimating telomere length from whole genome sequence data. Nucl Acids Res 2014; 42: e75.
93. Hemann MT., Strong MA., Hao LY., Greider CW. The shortest telomere., not average telomere length., is critical for cell viability and chromosome stability. Cell 2001;107:67-77.
94. Artandi SE., DePinho RA. Telomeres and telomerase in cancer. Carcinogenesis 2009; 31: 9-18.
95. Buseman CM., Wright WE., Shay JW. Is telomerase a viable target in cancer? Mutat Res 2012;730:90-7.
96. White LK., Wright WE., Shay JW. Telomerase inhibitors. Trends Bio-technol 2001;19:114-20.
97. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer 2008; 8: 167-79.
98. Autexier C., Greider CW. Telomerase and cancer: revisiting the telomere hypothesis. Trend Bioch Sci 1996;21:387-91.
99. Agrawal A., Dang S., Gabrani R. Recent patents on anti-telomerase cancer therapy. Recent Pat Anti cancer Drug Discov 2012;7:102-17.
100. Chiappori AA., Kolevska T., Spigel DR., Hager S., Rarick M., Gadgeel S., et al. A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. Annal Oncol 2015;26:354-62.
101. Baerlocker GM., Leibundgut EO., Ottmann OG., Spitzer G., Odenike O., McDivitt MA., et al. Telomerase inhibitor imetelstat in patients with essential thrombocythemia. New Engl J Med 2015; 373: 920-8.
102. Tefferi A., Lasho TL., Begna KH., Patnaik MM., Zblewski DL., Finke CM., et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. New Engl J Med 2015; 373: 908-19.
103. Mender I., Gryaznov S., Dikmen ZG., Wright WE., Shay JW. Induction of telomere dysfunction mediated by the telomerase substrate precursor., 6-thio-2-deoxyguanosine. Cancer Discov 2015;5: 82-95.
104. Holohan B., Wright WE., Shay JW. Impaired telomere maintenance spectrum disorders. J Cell Biology 2014; 205: 289-99.